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Abstract
Neuroendocrine prostate cancer (NEPrCa) arises de novo or after accumulation of genomic
alterations in pre-existing adenocarcinoma tumors in response to androgen deprivation ther-
apies. We have provided evidence that small extracellular vesicles released by PrCa cells
and containing the αVβ3 integrin promote neuroendocrine differentiation of PrCa in vivo and
in vitro. Here, we examined αVβ3 integrin expression in three murine models carrying a
deletion of PTEN (SKO), PTEN and RB1 (DKO), or PTEN, RB1 and TRP53 (TKO) genes in
the prostatic epithelium; of these three models, the DKO and TKO tumors develop NEPrCa
with a gene signature comparable to those of human NEPrCa. Immunostaining analysis of
SKO, DKO and TKO tumors shows that αVβ3 integrin expression is increased in DKO and
TKO primary tumors and metastatic lesions, but absent in SKO primary tumors. On the
other hand, SKO tumors show higher levels of a different αV integrin, αVβ6, as compared to
DKO and TKO tumors. These results are confirmed by RNA-sequencing analysis. More-
over, TRAMP mice, which carry NEPrCa and adenocarcinoma of the prostate, also have
increased levels of αVβ3 in their NEPrCa primary tumors. In contrast, the αVβ6 integrin is
only detectable in the adenocarcinoma areas. Finally, analysis of 42 LuCaP patient-derived
xenografts and primary adenocarcinoma samples shows a positive correlation between
αVβ3, but not αVβ6, and the neuronal marker synaptophysin; it also demonstrates that
αVβ3 is absent in prostatic adenocarcinomas. In summary, we demonstrate that αVβ3 integ-
rin is upregulated in NEPrCa primary and metastatic lesions; in contrast, the αVβ6 integrin is
confined to adenocarcinoma of the prostate. Our findings suggest that the αVβ3 integrin, but
not αVβ6, may promote a shift in lineage plasticity towards a NE phenotype and might serve
as an informative biomarker for the early detection of NE differentiation in prostate cancer.
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Introduction
Integrins are transmembrane adhesion receptors that are deregulated during cancer progres-
sion [1, 2]. Among others, αVβ6, αVβ3, α6β1, and α6β4 integrins are overexpressed in in pros-
tate cancer (PrCa) [3–6]; our group recently demonstrated that small extracellular vesicles
released from PrCa cells and containing the αVβ3 integrin induce neuroendocrine differentia-
tion (NED) in vitro and in vivo [7]. In contrast, the α5 and α7 integrin subunits have been
reported to be downregulated in PrCa [8].
The αVβ3 integrin, also known as the vitronectin receptor, is composed of two subunits,
αV and β3. It can bind a wide range of extracellular matrix components through its RGD
motif (Arg-Gly-Asp) [9] and promotes invasion and adhesion of cancer cells to extracellular
matrix proteins [2, 10, 11]. This RGD-integrin binding is also known to facilitate cell adhesion,
virus entry, and infection by many human viruses [12], including metapneumovirus [13] and
coxsackievirus [14]. According to a recent study, the interaction between the RGD motif in the
spike protein of the SARS-Cov-2 virus (responsible for COVID-19) and integrins may pro-
mote the entry of the virus into the host cells [15]. The αVβ3 integrin itself is involved in a vari-
ety of processes, including angiogenesis and tumor metastasis [16]. While present at very low
levels in normal prostate tissues, it is highly expressed in PrCa cells and in metastasis [7, 10,
17]. Given its widespread distribution in PrCa, αVβ3 has been explored as a therapeutic target
in some studies [18, 19].
Dysregulated expression of the αVβ6 integrin, another RGD binding integrin, has been
associated with poor outcomes in different types of cancer [20]. Previous studies from our
group showed that αVβ6 integrin is upregulated in PrCa and PrCa bone metastases [21, 22].
Neuroendocrine PrCa (NEPrCa), a subtype of PrCa that typically develops from subsets of
castrate-resistant PrCa (CRPrCa) cells, is highly aggressive and usually metastasizes [23].
NEPrCa tumors may develop de novo or through the acquisition of alterations in pre-existing
epithelial tumors in response to therapies as outlined in the recent National Cancer Institute
workshop “Perspective on Lineage Plasticity and AR-independent PrCa” [24]. De novo
NEPrCa appears to result from lineage reprogramming of mature differentiated cells that do
not express androgen receptor (AR) or prostate-specific antigen (PSA) but instead express
neuron-specific proteins, such as aurora kinase A (AURKA), synaptophysin (SYP), and neu-
ron-specific enolase (NSE) [25–27]. These aberrations promote pro-tumorigenic pathways
independently from those activated by the AR [28]. Treatment-emergent NEPrCa has similar
characteristics but, at variance, it acquires expression of the AR [29]. From a clinical perspec-
tive, NEPrCa quickly develops resistance to chemotherapy and is associated with a life expec-
tancy of less than one year [25, 30].
Here we show, for the first time, that αVβ3 integrin expression is increased in NEPrCa, but
absent in prostatic adenocarcinomas (ADPrCa). Our immunohistochemical analysis of PrCa
samples reveals differential expression of the αVβ3 and αVβ6 integrins. We find that the αVβ3
integrin is highly expressed in metastases from NEPrCa patients while αVβ6 integrin is mostly
expressed in ADPrCa lacking neuroendocrine features. We also show that αVβ3 expression is
increased in a murine model that lacks the PTEN, RB1, and TRP53 genes and develops
NEPrCa resembling its human counterpart. Loss of PTEN and RB1, with intact TRP53, also
causes increased expression of αVβ3 integrin, although to a lower extent. Moreover, we report
increased αVβ3 integrin expression in the tumors of TRAMP (Transgenic Adenocarcinoma of
the Mouse Prostate) mice that develop NEPrCa together with castrate-sensitive ADPrCa. We
confirmed these results by screening of 42 LuCaP patient-derived xenografts (PDXs) [31, 32].
Our analysis uncovers a positive correlation between αVβ3 integrin and SYP but not between
αVβ6 and this NE marker. Our study provides novel insights into the identification of new
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pathways that might promote lineage plasticity among PrCa subtypes for which there is no
established therapeutic approach. The differential expression of these two lineage-restricted
integrins might also serve as a useful biomarker to predict neuroendocrine differentiation and
facilitate patient stratification in PrCa.
Materials and methods
Cell lines
PrCa C4-2B and LNCaP cell culture conditions have been previously described [10, 33].
Antibodies
Immunohistochemistry (IHC) analysis used two different rabbit monoclonal antibodies (Abs)
against β3 integrin subunit: one from Cell Signaling (13166S; Figs 1 and 2) and another from
AbCam (Ab75872; Fig 4). Moreover, a rabbit polyclonal Ab against SYP (Invitrogen, PA1-
1043) and a rabbit polyclonal Ab against chromogranin A (CgA, Invitrogen, 18–0094) were
used. For the β6 integrin subunit, a mouse monoclonal Ab against the β6 integrin subunit
(6.2A1) [34] was used for immunostaining of human samples, and a human/mouse chimeric
Ab against the β6 integrin subunit (ch2A1) [35] was used for SKO, DKO, and TKO murine
samples. Immunoblotting analysis used rabbit monoclonal Ab against β3 integrin subunit
(Cell Signaling, 13166S), rabbit polyclonal Abs against TSG101 (Abcam, ab30871), actin
(Sigma, A2066), and a mouse monoclonal Ab against the β6 integrin subunit (6.2A1).
Generation of mice carrying prostate-specific TRP53 and RB1 gene
deletions
Mice of genotype PB-Cre4 PTENloxP/loxP, PB-Cre4 PTENloxP/loxPRB1loxP/loxP, or PB-Cre4
PTENloxP/loxP RB1loxP/loxPTRP53loxP/loxP were generated as previously described [36, 37]. Briefly,
mice carrying different combinations of the PTENloxP, RB1loxP, and TRP53loxP alleles were
interbred, with the ARR2PB-Cre transgene from the PB-Cre4 line always carried through
males. Mice used in this analysis are on a C57BL/6 and 129SVJ mixed genetic backgrounds.
Mice were backcrossed to the C57BL/6 strain for at least 5 generations. Genotypes were desig-
nated as SKO (single PTEN knock-out), DKO (double PTEN:RB1 knock-out), and TKO (triple
PTEN:RB1:TRP53 knock-out). Non-recombinant littermates were used as a control. The mice
were euthanized using CO2 and cervical dislocation when the tumor length was approximately
2 cm. All of these mice were maintained following guidelines of the Institutional Animal Care
and Use Committee (IACUC), and were bred and kept at Roswell Park Comprehensive Can-
cer Center (Buffalo, NY, USA).
TRAMP (Transgenic Adenocarcinoma of the Mouse Prostate) mice
Male TRAMP mice were generated as described previously [38]. Twenty-four male TRAMP
mice were used. No female mice were analyzed in this study. The mice were euthanized using
CO2 and cervical dislocation when the tumor volume was approximately 10,000 mm
3. Care of
animals was in compliance with standards established by the Office of Laboratory Animal
Welfare, NIH, Department of Health and Human Services. All mice were maintained follow-
ing recommendations of the IACUC. Experimental protocols were approved by IACUC.
PDX establishment
The acquisition of PrCa patient tissues and their use to establish PDX models have been
described [32]. The vast majority of implanted tissues was from metastatic foci obtained at
PLOS ONE The αVβ3 integrin is a marker of neuroendocrine prostate cancer
PLOS ONE | https://doi.org/10.1371/journal.pone.0244985 January 22, 2021 3 / 19
tissue acquisition necropsy in a manner which limited warm ischemic time as much as possible
(aiming for 4–8 hours after death). A few samples of primary PrCa were obtained from surgical
procedures. Harvested tumor tissues were evaluated by pathologists, and viable tumor tissue
was macro-dissected to minimize content of stroma, fat, and necrotic tissue. Tumor fragments
were implanted subcutaneously in 6- to 8-week-old intact male athymic Nu/Nu (NU-
Foxn1nu) or CB-17 severe combined immunodeficient (SCID, CB17/Icr-Prkdcscid/IcrCrl)
mice (Charles River Laboratory). Tumor samples were harvested from later passages (>3) and
frozen or embedded in paraffin for characterization. LuCaP PDXs are maintained by constant
passaging in SCID mice. The levels of SYP in the LuCaP PDX were assessed by IHC analysis.
Fig 1. αVβ3 integrin is selectively upregulated in the primary tumors of mice carrying neuroendocrine prostate cancer. Immunostaining of the αVβ3 integrin (top
panels), αVβ6 integrin (middle panels), and SYP (bottom panels) in prostate tumors from murine models with genetic knockdown of PTEN (SKO; n = 5), PTEN and
RB1 (DKO; n = 5), and PTEN, RB1, and TRP53 (TKO; n = 5) in the prostatic epithelium. The bar at the bottom right corner of each panel represents 50 μm. First
column: SKO; second column: DKO; third column: TKO.
https://doi.org/10.1371/journal.pone.0244985.g001
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Immunohistochemistry (IHC)
IHC was performed on tissue sections from SKO (n = 5), DKO (n = 5), and TKO (n = 5) pros-
tate tumors and lung metastases, from TRAMP murine primary tumors, and on LuCaP PDX
TMA containing 42 PDX models. Of the 24 TRAMP mice analyzed, 13 exhibited a NE pheno-
type, 11 presented adenocarcinoma lesions, and 5 displayed both characteristics. The tissue
sections were baked at 60˚C for 1 hour, followed by deparaffinization with xylene (3 min × 2),
and rehydration through a graded ethanol series (100%, 90%, 70%, 50%, 30% for 3 min each)
followed by deionized water (3 min × 2). The sections were incubated with 3% H2O2 solution
for quenching endogenous peroxidase activity, followed by heat-induced antigen retrieval for
the β3 integrin subunit, SYP or chromogranin (CgA) that was performed in citrate buffer (10
mM sodium citrate, 0.05% Tween 20, pH 6.0) at 95˚C for 15 min. For β6 integrin subunit
immunostaining, antigen retrieval was performed using pepsin (0.5% in 5 mM HCl) digestion
for 15 min at 37˚C. Sections were washed once with deionized water for 5 min, followed by a
phosphate buffer saline (PBS) wash for 5 min, and blocked with 5% goat serum in PBST (PBS,
0.1% Tween20) for 2 hours. The tissue sections were incubated overnight at 4˚C with Abs
against β3 integrin subunit (1:25), β6 integrin subunit (2 μg/ml), CgA (1 μg/ml), SYP (5 μg/
ml), or the respective IgG isotype, which was used as negative control. The following day, the
tissue sections were washed with PBST (5 min × 2), followed by PBS (5 min), and incubated
with secondary Abs (biotinylated goat anti-rabbit IgG in PBST for β3 integrin, SYP, or CgA,
and biotinylated goat anti-human or horse anti-mouse IgG for β6 integrin, 10 μg/ml in PBST)
for 30 min at room temperature. The unbound secondary Ab was washed with PBST (5
min × 2), followed by PBS (5 min). The tissue sections were incubated with streptavidin horse-
radish peroxidase (SAP, 5 μg/ml in PBS) for 30 min at room temperature and the unbound
SAP was washed with PBST (5 min × 2), followed by PBS (5 min). The chromogenic reaction
product was developed by adding substrate chromogen 3,30-diaminobenzidine solution (DAB
substrate kit). The DAB reaction was stopped by rinsing the tissue sections in deionized water.
The sections were counterstained with Harris hematoxylin, dehydrated in a graded ethanol
series (30%, 50%, 70%, 90%, 100% for 5 min each) followed by xylene (5 min × 2), dried, and
finally mounted with Permount (Vector Laboratories).
LuCaP TMA immunohistochemical assessment and statistical analysis
LuCaP PDX TMA immunostaining was scored by multiplying each staining intensity level (“0”
for no stain, “1” for faint stain, and “2” for definitive stain) by the percentage of cells at each stain-
ing level. The multiplicands provided a final score for each sample (score range was 0 to 200). The
score for each LuCaP core was the average of the scores of each triplicate. Relative detection levels
of SYP were provided by Dr. Corey and defined as 0 (-), 1 (+), 2 (++), and 3 (+++). The normali-
zation was performed by assigning to the higher score for each immunostaining (αVβ3, αVβ6,
and SYP) a value of 100. Correlation analysis between the integrin scores and the expression levels
of SYP and its significance was performed using Spearman correlation (Matlab v.R2016a).
RNA-sequencing (RNA-seq)
RNA-seq was performed as previously reported in [39] and publicly available on GEO Expres-
sion Omnibus (accession number: GSE90891). Briefly, RNA-seq was performed on SKO
Fig 2. αVβ3 integrin is selectively upregulated in lung metastases of mice carrying neuroendocrine prostate cancer. Immunostaining of the αVβ3 integrin (top
panels), αVβ6 integrin (middle panels), and SYP (bottom panels) in the lung metastases from murine models with genetic knockdown of PTEN and RB1 (DKO; n = 5)
and PTEN, RB1, and TRP53 (TKO; n = 5) in the prostatic epithelium. The bar at the bottom right corner of each panel represents 20 μm. First column: DKO; second
column: TKO.
https://doi.org/10.1371/journal.pone.0244985.g002
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(n = 4), DKO (n = 5), and TKO (n = 4) prostate tumors and on normal prostate (n = 4) by the
Roswell Park Cancer Institute Genomics shared resource. Sequencing libraries were prepared
with the TruSeq Stranded Total RNA kit (Illumina Inc) from 1 μg total RNA following manu-
facturer’s instructions. After ribosomal RNA depletion, RNA was purified, fragmented, and
primed for cDNA synthesis. Fragmented RNA was reverse transcribed into first-strand cDNA
using random primers. AMPure XP beads were used to separate the cDNA from the second-
strand reaction mix resulting in blunt-ended cDNA. A single ‘A’ nucleotide was then added to
the 3’ ends of the blunt fragments. Multiple indexing adapters, containing a single ‘T’ nucleo-
tide on the 3’ end of the adapter, were ligated to the ends of the cDNA to prepare them for
hybridization onto a flow cell. Libraries were purified and validated for the appropriate size on
a 2100 Bioanalyzer High Sensitivity DNA chip (Agilent Technologies, Inc.). The DNA library
was quantitated using KAPA Biosystems qPCR kit and normalized to 2 nM prior to pooling.
Libraries were pooled in an equimolar fashion and diluted to 10 pM. Library pools were clus-
tered and run on a HiSeq2500 rapid mode sequencer according to the manufacturer’s recom-
mended protocol (Illumina Inc.).
Raw sequencing reads passing the Illumina RTA quality filter were pre-processed using
FASTQC for sequencing base quality control. Reads were mapped to the mouse reference
genome (mm9) and RefSeq annotation database using Tophat. A second round of quality con-
trol using RSeQC was applied to mapped bam files to identify potential RNA-seq library prep-
aration problems. The number of reads aligning to each gene was calculated using HTSeq, and
for each gene, the corresponding RPKM value was calculated.
For differential gene expression analysis, RNA-seq counts were processed to remove genes
lacking expression in more than 80% of samples. Scale normalization was done using the
Limma package in R. After Voom transformation, data from primary SKO, DKO, and TKO
tumors were compared to generate differentially expressed gene lists with P < 0.05 and
logFC > 1.5.
Human subject inclusion criteria
Three metastatic ADPrCa tissue samples (Gleason Score GS 9 [n = 1] and GS 10 [n = 2]) were
obtained from the Department of Pathology at Thomas Jefferson University (Philadelphia,
PA). Additionally, four human malignant ADPrCa tissue samples (GS 7 [n = 3] and GS 10
[n = 1]) were obtained from the Cooperative Human Tissue Network (CHTN) Western Divi-
sion at Vanderbilt University Medical Center, TN, or Mid-Atlantic Division at University of
Virginia, VA. The CHTN is funded by the National Cancer Institute and other investigators
may have received specimens from the same subjects. All specimens were de-identified and
discarded in accordance with IRB-approved protocols.
siRNA transfection and immunoblotting analysis
Downregulation of AR was accomplished using siRNA SMARTPool (Dharmacon, L-003400-
00-0005) and non-targeting siRNA as a control (Dharmacon, D-001810-10-05). Transfection
of siRNA and immunoblotting analysis were performed as previously described [21].
Results
The αVβ3 integrin is selectively upregulated in NEPrCa murine models
In a recent study, we have shown that the αVβ3 integrin is found in small extracellular vesicles
released by cancer cells and that small extracellular vesicles containing αVβ3 have a unique
ability to promote NED of PrCa in vivo [7]. Based on these findings, we hypothesized that
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elevated expression levels of αVβ3 might correlate with NED in PrCa. We tested this hypothe-
sis by analyzing the levels of αVβ3 and αVβ6 integrins in primary tumors, as well as lung meta-
static lesions, from NEPrCa mice carrying PTEN, RB1, and TRP53 triple conditional knock-
outs in the prostatic epithelium (PBCre4 PTENloxP/loxP RB1loxP/loxPTRP53loxP/loxP, TKO). This
model has been reported to develop NEPrCa similar to its human counterpart [39]. We com-
pared the TKO model to a double knock-out model lacking PTEN and RB1 in the prostate
(PBCre4 PTENloxP/loxP RB1loxP/loxP, DKO). In addition, we analyzed a PTEN single conditional
knock-out mouse model (PBCre4 PTENloxP/loxP, SKO) whose gene expression signature has
been shown to be comparable to human ADPrCa [39]. The immunostaining analysis reveals
high levels of the αVβ3 integrin (Figs 1 and 2, top panels) which correlate with SYP expression
(Figs 1 and 2, bottom panels) in the prostate tumors (Fig 1) and lung metastatic lesions (Fig 2)
of DKO and TKO mice (n = 5 for each group). The results are consistent in all samples except
for one of the DKO samples which does not exhibit detectable αVβ3 integrin expression. In
the tumors from the SKO mice, the αVβ3 integrin is not detectable (Fig 1, top panels), whereas
the αVβ6 integrin is highly expressed in SKO prostate tumor samples (Fig 1, middle panels),
and is low with some patchy positivity in the DKO and TKO primary tumors (Fig 1, middle
panels). Consistent with these results, lung metastatic lesions from DKO and TKO mice show
some patchy positivity for the αVβ6 integrin (Fig 2, middle panels) but at a considerably lower
level than for αVβ3. We did not observe any metastases in SKO mice.
Consistent with the immunostaining results, RNA sequencing analysis of the publicly avail-
able datasets on Geo Expression Omnibus (GSE90891, [39]) reveals higher levels of the β3
integrin subunit (ITGB3) expression in DKO and TKO tumors compared to SKO samples.
Moreover, ITGB3 mRNA is upregulated in SKO compared to normal prostate (wild type, WT;
Table 1), although our immunostaining analysis does not detect the αVβ3 integrin in the SKO
samples analyzed (Fig 1). These results indicate that, although the ITGB3 mRNA is present in
SKO tumors, the mRNA is likely to be unstable. In addition, the levels of the αV integrin sub-
unit (ITGAV) and β6 integrin subunit (ITGB6) are lower in DKO and TKO tumors compared
to SKO, although noticeably higher in all three knock-out genotypes compared to normal
prostate (WT) samples (Table 1).
NEPrCa expresses elevated levels of PARP1 which is a nuclear enzyme involved in DNA
repair, DNA replication, inflammation, and chromosome organization [40, 41]. Consistent
with these previous publications, PARP1 expression is upregulated in DKO and TKO tumors
(Table 1). Although PARP1 mRNA is also upregulated in SKO samples compared to the WT
control, the levels of PARP1 mRNA are not as elevated as in DKO and TKO tumors (Table 1).
In addition, another gene involved in NED (BRN4 [POU3F4]) [42] is upregulated in DKO and
TKO samples but not in SKO (Table 1). These results demonstrate that high expression of
ITGB3 and of genes implicated in NED co-occur in DKO and TKO tumors.
Table 1. RNA sequencing analysis shows increased expression of ITGB3 mRNA in DKO and TKO tumors.
WT (n = 4) SKO (n = 4) DKO (n = 5) TKO (n = 4)
ITGB3 23.8 1145.5 3536.4 3018
ITGAV 764.3 22121.3 3262.6 4857.3
ITGB6 22.8 3652.5 2113.8 1033
PARP1 580.8 4434.3 15946.2 10862.5
POU3F4 0 0 86.6 75.5
Normalized read counts for the β3 integrin subunit (ITGB3), αV integrin subunit (ITGAV), β6 integrin subunit (ITGB6), PARP1, and BRN4 (POU3F4) RNA levels in
normal prostate (WT), as well as in SKO, DKO, and TKO prostate tumor samples.
https://doi.org/10.1371/journal.pone.0244985.t001
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We also performed immunohistochemical analysis of tumor samples from TRAMP mice to
assess the levels of αVβ3 and αVβ6 integrin expression in their tumors. This mouse model,
which is known to have RB and p53 inactivated, develops NEPrCa together with ADPrCa [43,
44]. Our immunostaining shows that the NE marker chromogranin A (CgA) co-occurs with
the αVβ3 integrin in 10 of the 13 TRAMP NE tumor samples analyzed (Fig 3). The αVβ6
integrin, however, is not detected in the NE tumors from the TRAMP model (Fig 3). In con-
trast, the αVβ6 integrin is detected exclusively in the ADPrCa, NE-negative areas of the
TRAMP tumor samples (Fig 3). Our results, from the DKO and TKO NE mouse genetic mod-
els as well as the TRAMP mice, taken together, clearly demonstrate a consistent correlation
between the high expression of αVβ3 integrin and NEPrCa occurrence. Conversely, ADPrCa
tumors are consistently associated with expression of the alternative αVβ6 integrin subtype.
Expression of αVβ3 integrin and synaptophysin correlates in patient-
derived xenografts
To confirm these results in human specimens, we conducted an immunohistochemical analysis
of 42 LuCaP PDXs [31, 32]. These PDX models were generated by implanting primary PrCa or
metastatic lesion tumor fragments from PrCa patients into immunocompromised mice [32], and
the resulting PDX models were subsequently characterized for their expression of NE markers
[31]. We assessed the presence of αVβ3 or αVβ6 integrin using immunohistochemical analysis
and scored the immunostaining intensity of each LuCaP core in the tumor micro-array (TMA)
using the scoring system described in the Materials and Methods section. We observe a positive
correlation between the αVβ3 integrin and the NE marker SYP (Fig 4A and 4B, r = 0.42;
P = 0.0046). In contrast, the αVβ6 integrin shows no correlation with SYP (Fig 4A and 4B,
r = 0.22; P = 0.1622), confirming the results described above obtained for mouse tumor samples.
We further validated the results obtained using the LuCaP PDX TMA by screening PrCa
samples from the Department of Pathology at Thomas Jefferson University and the Coopera-
tive Human Tissue Network. Of the 7 ADPrCa primary tumors none expresses αVβ3 (Fig 4C).
On the other hand, as previously reported [21], most of the ADPrCa express αVβ6 which was
used as positive control. These findings suggest a differential expression of these two αV integ-
rins during PrCa progression, whereby the αVβ3 integrin is specifically expressed in NEPrCa
samples, and in contrast, the αVβ6 integrin is specifically expressed in ADPrCa samples lack-
ing NE characteristics.
Loss of androgen receptor signaling does not result in upregulation of
αVβ3 or αVβ6 integrin expression in PrCa cell lines
NEPrCa is characterized by the activation of pro-tumorigenic pathways independently from
the AR signaling [28]. We hypothesized that loss of AR signaling might induce upregulation of
the αVβ3 integrin in LNCaP and C4-2B, two AR positive PrCa cell lines. To test our hypothe-
sis, we downregulated AR expression in LNCaP and C4-2B cells using siRNA. Our results
show that downregulation of AR in C4-2B or LNCaP cells does not upregulate αVβ3 (Fig 5A)
or αVβ6 integrin (Fig 5B) expression. Thus, it is possible that other factors in the tumor micro-
environment contribute to the regulation of αVβ3 integrin and αVβ6 integrin expression after
AR signaling loss.
Discussion
Our results demonstrate that increased expression of the αVβ3 integrin correlates with the
occurrence of NE markers in human patients’ samples and murine models. In contrast, the
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Fig 3. Selective upregulation of αVβ3 integrin in the TRAMP (Transgenic Adenocarcinoma of the Mouse Prostate) mice. IHC staining
of αVβ3 (first row), αVβ6 (second row), and chromogranin A (CgA, third row) of prostate tumors from TRAMP mice (n = 24). Of the 24
samples analyzed, 13 show only a NE phenotype, 11 show only ADPrCa lesions, and 5 show both characteristics. IgG was used as negative
control (last row). The bar at the bottom right corner of each panel represents 50 μm. Left column, ADPrCa; right column, NEPrCa.
https://doi.org/10.1371/journal.pone.0244985.g003
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Fig 4. Increased expression of the αVβ3 integrin, but not αVβ6, correlates with the neuroendocrine marker SYP in LuCaP PDXs and human prostate tumor
samples. Immunohistochemical analysis of 42 LuCaP PDX models. (A) representative IHC staining for αVβ3 (left) or αVβ6 (right) integrin of SYP positive (top row) or
SYP-negative (bottom row) LuCaP PDX models is shown. The bar at the bottom right corner of each panel represents 20 μm. (B) Heat map of the signature score for SYP,
αVβ3 or αVβ6 integrin of each LuCaP is shown. Raw data are reported in the S1 Table. (C) Immunostaining analysis of αVβ3 and αVβ6 integrins and SYP primary
tumors from ADPrCa patients. The bar at the bottom right corner of each panel represents 20 μm.
https://doi.org/10.1371/journal.pone.0244985.g004
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αVβ6 integrin is expressed in human and murine ADPrCa, suggesting that the αVβ3, but not
αVβ6, integrin might serve as a suitable biomarker to characterize NED in the context of PrCa.
Here, we show that these two integrins are differentially expressed in ADPrCa and NE can-
cers. Specifically, expression of the αVβ3 integrin in primary prostate tumors and metastatic
lesions of mice carrying deletions of the PTEN (SKO), RB1 and PTEN (DKO) or RB1, PTEN,
and TP53 (TKO) inversely correlates with αVβ6. Expression of the αVβ3 integrin in primary
prostate tumors of mice carrying deletions of the PTEN (SKO) is undetectable, while it is sig-
nificantly increased in DKO or TKO tumors and metastatic lesions. This indicates that RB1
loss, and consequent activation of transcription factors of the E2F family [45–47], is sufficient
to induce αVβ3 expression in these models. This integrin expression persists in TKO tumors
which, in contrast to DKO tumors exhibiting both SYP and AR expression, develop homoge-
nous AR-negative NEPrCa, similar to its human counterpart [39]. It remains to be investigated
whether downregulation of αVβ6 and gain of the αVβ3 integrin occur in CRPrCa since RB1 is
known to influence integrin expression [48, 49], and its loss occurs frequently in human
CRPrCa [50, 51].
A factor that may influence the processing of the αVβ3 integrin, is the expression of the αV
subunit which is required for the heterodimeric complex. The RNA analysis summarized here
(Table 1) indicates that the levels of the αV integrin subunit (ITGAV) become limiting and
that β3 acts in a dominant fashion over the β6 integrin subunit.
Fig 5. Downregulation of androgen receptor does not increase αVβ3 or αVβ6 integrin expression. Immunoblotting analysis
of C4-2B and LNCaP cell lysates after AR downregulation by siRNA to AR. (A) Expression levels of αVβ3 integrin in C4-2B and
LNCaP cells after AR downregulation. Immunoblotting was performed under reducing conditions. (B) Expression levels of
αVβ6 integrin in C4-2B and LNCaP cells after AR downregulation. Immunoblotting was performed under non-reducing
conditions. Actin or TSG101 serves as loading controls. NS, non-silencing.
https://doi.org/10.1371/journal.pone.0244985.g005
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We also detect high αVβ3 integrin expression in the NE areas of primary tumors from
TRAMP mice that develop NEPrCa together with ADPrCa. In contrast, we detect the related
αVβ6 integrin in the ADPrCa areas of the TRAMP tumors. Our findings underline the speci-
ficity of the αVβ3 integrin in NEPrCa, nominating this integrin as a potential biomarker for
patient stratification in PrCa treatment. Our future studies will benefit from the use of mice
carrying deletion of the αVβ3 integrin crossed with the DKO, TKO, or TRAMP mice, in order
to shed new light on the mechanism of action of the αVβ3 integrin in NEPrCa development
and/or metastatic progression.
Multiple strategies have been developed to target the αVβ3 integrin due to its role in tumor
angiogenesis and tumor growth [16]. For example, LM609, an inhibitory antibody against the
αVβ3 integrin, reduced angiogenesis and tumor growth in a SCID mouse/human chimeric
model for breast cancer [52]. Its humanized counterpart JC-7U IgG1 has been reported to inhibit
tumor growth in a Kaposi sarcoma mouse model and was also able to inhibit, in part, the binding
of human immunodeficiency virus (HIV-1) Tat protein to αVβ3 integrin, which is necessary to
stimulate Kaposi sarcoma growth [16, 53]. Previous studies also reported the ability of the αVβ3
integrin to support metastasis in PrCa [54] as well as other cancers [55–58]. Likewise, the expres-
sion of the αVβ3 integrin conceivably facilitates the metastatic behavior of NEPrCa. In support of
this idea, our SKO mouse model (PB-Cre4 PTENloxP/loxP) does not metastasize and expresses low
levels of αVβ3 integrin, whereas DKO and TKO, the two NE models that acquire αVβ3 integrin
expression as a consequence of additional RB1 knock-out, develop metastases in the lungs [39].
We can speculate that upon RB1 loss, downregulation of αVβ6 and gain of the αVβ3 integrin are
required in the primary tumors in the early stages of NED to confer upon NEPrCa the ability to
metastasize in different sites (Fig 6). Upon metastasizing, the αVβ3 integrin expression is sus-
tained as shown here and as previously described [7] in NEPrCa bone metastasis, indicating addi-
tional pro-survival functions provided by this integrin.
Whether one or more of the many pathways activated by the αVβ3 integrin is involved in
NED remains to be established. For example, the expression of the αVβ3 integrin reportedly
stimulates cell migration by activation of the phosphatidylinositol 3-kinase (PI3K)/AKT pathway
[59]. Other studies have demonstrated that AKT1 is involved in stabilizing N-MYC [60, 61], one
of the main promoters of NED in PrCa [62]. Since pAKT is not detectable in TKO prostate tissue
[39], we speculate that pAKT activated by αVβ3 primes the cells to stabilize N-MYC but is not
required for long-lasting NED. The RNA-seq analysis presented here highlights potential down-
stream effectors of αVβ3. For example, αVβ3 integrin might be able to induce NED in PrCa by
upregulating Trop2 expression, which is known to induce NEPrCa by upregulation of PARP1
[40]. Underlining the importance of targeting this pathway to prevent or delay the most aggres-
sive forms of PrCa, the U.S. Food and Drug Administration has recently approved olaparib, a
PARP1 inhibitor [63], for the treatment of metastatic CRPrCa. However, there are as yet no
reports on the safety or efficacy of olaparib for the treatment of NEPrCa.
Our previous study demonstrates that the dysregulated expression of the αVβ3 integrin in
small extracellular vesicles released by PrCa cells promotes a shift in lineage plasticity towards a
NE lineage [7]. Moreover, although our group has reported that the αVβ6 integrin, in small
extracellular vesicles released by cancer cells, induces M2 polarization in recipient monocytes
[64] and stimulates angiogenesis in endothelial cells during cancer progression [65], is absent in
NEPrCa. Here we show that the αVβ3 integrin is upregulated in tumor samples from patients
affected by NEPrCa and in corresponding NE murine models. Moreover, our findings demon-
strate that conversely, the expression of the αVβ6 integrin is upregulated in ADPrCa samples
from humans and mice. It is therefore reasonable to speculate that monitoring the expression of
these two integrins during PrCa progression will help to predict the potential for NED in PrCa
patients. Moreover, based on our emerging findings that NE metastatic lesions express relatively
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high levels of the αVβ3 integrin, targeted therapies directed against this integrin might prove to
be effective in preventing or delaying plasticity and metastasis in NEPrCa [56].
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